EGFR and non-small cell lung carcinoma: In addition, Li et al. investigated the role of autophagy in osimertinib resistance in non-small cell lung cancer (NSCLC) and found that increased autophagy was associated with resistance to the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).